Activist investor Starboard Value said Thursday it intends to use its stake in Bristol-Myers Squibb to oppose the drugmaker's $74 billion acquisition of Celgene.
The activist fund has also nominated a slate of director candidates that it hopes to elect at Bristol's 2019 annual shareholder meeting. "The actions we are taking — specifically, our intent to solicit shareholders to block the proposed acquisition of Celgene — are not taken lightly," Smith added."This view has been solidified by the numerous other large, long-term shareholders who appear to likewise believe this deal is not in the best interest of shareholders."
Investment firm Wellington Management on Wednesday also announced its opposition. Wellington said it"does not believe that the Celgene transaction is an attractive path towards" business that"secures differentiated science and broadens the future revenue base."
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Source: CNBC - 🏆 12. / 72 Read more »
Starboard Details Opposition to Bristol-Myers Deal for CelgeneActivist investor Starboard Value detailed its opposition to Bristol-Myers Squibb’s proposed acquisition of Celgene, describing the proposed takeover as poorly conceived and ill advised. CNBC Faber reported that WELLINGTON MGT. was the force behind the deal-break, even tho their voting rights aren't as large as their holdings. Also that STARBD held comparatively little stock. Was he wrong ?
Source: WSJ - 🏆 98. / 63 Read more »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisitionSynergies almost never end up creating the shareholder value expected. See KHC over last 2 years.
Source: CNBC - 🏆 12. / 72 Read more »
Bristol-Myers $74 bln deal needs surgeryBig shareholder Wellington Management and activist Starboard Value have both come out against the pharma firm’s deal for Celgene. The market also isn’t pricing in the acquisition happening as Bristol-Myers envisaged. It doesn’t help that the buyer was already overpaying. ReutersBiz rob_cyran PLEASE STOP, THE LENGTH OF YOUR NAME IS GOING TO REACH CRITICAL MASS.
Source: Breakingviews - 🏆 470. / 51 Read more »
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Source: CNBC - 🏆 12. / 72 Read more »